Ionis Pharmaceuticals, Inc. (IONS) Earnings History
Annual and quarterly earnings data from 1991 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 98.3% | -40.5% | -40.4% |
| 2024 | 98.4% | -67.4% | -64.4% |
| 2023 | 98.8% | -44.9% | -46.5% |
| 2022 | 97.6% | -69.8% | -45.9% |
| 2021 | 98.7% | -3.7% | -3.5% |
Download Data
Export IONS earnings history in CSV or JSON format
Free sign-in required to download data
Ionis Pharmaceuticals, Inc. (IONS) Earnings Overview
As of February 28, 2026, Ionis Pharmaceuticals, Inc. (IONS) reported trailing twelve-month net income of -$381M, reflecting +0.2% year-over-year growth. The company earned $-2.35 per diluted share over the past four quarters, with a net profit margin of -0.4%.
Looking at the long-term picture, IONS's historical earnings data spans multiple years. The company achieved its highest annual net income of $278M in fiscal 2019.
Ionis Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including ALNY ($314M net income, 0.1% margin), ARWR ($202M net income, -0.0% margin), CRSP (-$488M net income, -165.7% margin), IONS has room to improve margins relative to the peer group. Compare IONS vs ALNY →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
35 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$381M | +16.1% | -$382M | $-2.38 | -40.4% | -40.5% |
| 2024 | -$454M | -23.9% | -$475M | $-3.04 | -64.4% | -67.4% |
| 2023 | -$366M | -35.8% | -$354M | $-2.56 | -46.5% | -44.9% |
| 2022 | -$270M | -843.2% | -$410M | $-1.90 | -45.9% | -69.8% |
| 2021 | -$29M | +93.6% | -$30M | $-0.20 | -3.5% | -3.7% |
| 2020 | -$444M | -259.7% | -$172M | $-3.18 | -60.9% | -23.6% |
| 2019 | $278M | +1.6% | $366M | $2.06 | 24.8% | 32.6% |
| 2018 | $274M | +79015.9% | -$61M | $2.04 | 45.6% | -10.2% |
| 2017 | $346,000 | +100.6% | $31M | $-0.05 | 0.1% | 6.0% |
| 2016 | -$60M | +31.6% | -$20M | $-0.72 | -16.2% | -5.4% |
See IONS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IONS Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare IONS vs AGIO
See how IONS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is IONS growing earnings?
IONS EPS of $-2.35 reflects slowing growth at +0.2%, below the 5-year CAGR of N/A. TTM net income is $-381M. Expansion rate has moderated.
What are IONS's profit margins?
Ionis Pharmaceuticals, Inc. net margin is -0.4%, with operating margin at -0.4%. Below-average margins reflect competitive or cost pressures.
How consistent are IONS's earnings?
IONS earnings data spans 1991-2025. The current earnings trend is +0.2% YoY. Historical data enables comparison across business cycles.